Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

Fang Jen Wu, Shiow Yunn Sheu, Herng Ching Lin, Shiu Dong Chung

研究成果: 雜誌貢獻文章

7 引文 (Scopus)

摘要

Objective To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. Methods We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. Results The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. Conclusion The present findings suggest that patients with PC who had received ADT had an increased risk of falls.
原文英語
頁(從 - 到)145-150
頁數6
期刊Urology
95
DOIs
出版狀態已發佈 - 九月 1 2016

指紋

Androgens
Prostatic Neoplasms
Confidence Intervals
Therapeutics
Urbanization
Health Insurance
Hyperlipidemias
Taiwan
Coronary Disease
Parkinson Disease
Epilepsy
Stroke
Databases
Hypertension
Incidence
Population

ASJC Scopus subject areas

  • Urology

引用此文

Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. / Wu, Fang Jen; Sheu, Shiow Yunn; Lin, Herng Ching; Chung, Shiu Dong.

於: Urology, 卷 95, 01.09.2016, p. 145-150.

研究成果: 雜誌貢獻文章

@article{5c31fadf5df64d38b5fe3e4f21594d0f,
title = "Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer",
abstract = "Objective To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. Methods We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95{\%} confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. Results The incidence rates of falls per 1000 person-years were 13.37 (95{\%} CI: 9.15~18.88) and 6.44 (95{\%} CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95{\%} CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. Conclusion The present findings suggest that patients with PC who had received ADT had an increased risk of falls.",
author = "Wu, {Fang Jen} and Sheu, {Shiow Yunn} and Lin, {Herng Ching} and Chung, {Shiu Dong}",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.urology.2016.05.058",
language = "English",
volume = "95",
pages = "145--150",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Increased Fall Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer

AU - Wu, Fang Jen

AU - Sheu, Shiow Yunn

AU - Lin, Herng Ching

AU - Chung, Shiu Dong

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Objective To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. Methods We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. Results The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. Conclusion The present findings suggest that patients with PC who had received ADT had an increased risk of falls.

AB - Objective To examine the relationship between the use of androgen deprivation therapy (ADT) and the subsequent risk of falls in men with prostate cancer (PC) by employing a population-based dataset. Methods We retrieved the study sample from the Taiwan Longitudinal Health Insurance Database 2005. We included 886 patients with PC who had received ADT as the study group, whereas 862 patients with PC who had not received ADT served as the comparison group. We then individually tracked each study patient for a 3-year period to identify those who subsequently received a diagnosis of a fall. We performed Cox proportional hazard regressions to calculate the hazard ratio (HR) and its corresponding 95% confidence interval (CI) for a fall during the 3-year follow-up period between these 2 groups. Results The incidence rates of falls per 1000 person-years were 13.37 (95% CI: 9.15~18.88) and 6.44 (95% CI: 3.61~10.63), respectively, for patients with PC who received ADT and those who did not receive ADT. Furthermore, the hazard ratio for a fall during the 3-year follow-up period for patients with PC who had received ADT was 1.95 (95% CI: 1.04~3.66, P = .037) compared to those who had not received ADT after censoring sampled patients who died during the 3-year follow-up period and adjusting for age, geographical location, monthly income, urbanization level, hypertension, diabetes, hyperlipidemia, coronary heart disease, Parkinson's disease, epilepsy, stroke, and mental illness. Conclusion The present findings suggest that patients with PC who had received ADT had an increased risk of falls.

UR - http://www.scopus.com/inward/record.url?scp=84991013877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991013877&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2016.05.058

DO - 10.1016/j.urology.2016.05.058

M3 - Article

C2 - 27318262

AN - SCOPUS:84991013877

VL - 95

SP - 145

EP - 150

JO - Urology

JF - Urology

SN - 0090-4295

ER -